Ghent University Academic Bibliography

Advanced

H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses

Philippe Moris, Robbert van der Most, Isabel Leroux-Roels UGent, Frédéric Clement UGent, Mamadou Dramé, Emmanuel Hanon, Geert Leroux-Roels UGent and Marcelle Van Mechelen (2011) JOURNAL OF CLINICAL IMMUNOLOGY. 31(3). p.443-454
abstract
Objective Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses. Methods Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75-30 mu g hemagglutinin and formulated with or without adjuvant were administered to groups of 50 volunteers aged 18-60 years. Results Adjuvantation of the vaccine led to better persistence of neutralizing and hemagglutination-inhibiting antibodies and higher frequencies of antigen-specific memory B cells. Cross-reactive and polyfunctional H5N1-specific CD4 T cells were detected at baseline and were amplified by vaccination. Expansion of CD4 T cells was enhanced by adjuvantation. Conclusion Formulation of the H5N1 vaccine with AS03(A) enhances antibody persistence and induces stronger T- and B-cell responses. The cross-clade T-cell immunity indicates that the adjuvanted vaccine primes individuals to respond to either infection and/or subsequent vaccination with strains drifted from the primary vaccine strain.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
AS03(A), CHALLENGE, H5N1, vaccine, MEMORY B-CELLS, CANDIDATE VACCINE, REVERSE GENETICS, A H5N1, GENERATION, IMMUNITY, ADULTS, CD4 T cells, pandemic influenza, INFECTION, ADJUVANTS
journal title
JOURNAL OF CLINICAL IMMUNOLOGY
J. Clin. Immunol.
volume
31
issue
3
pages
443 - 454
Web of Science type
Article
Web of Science id
000292556000017
JCR category
IMMUNOLOGY
JCR impact factor
3.077 (2011)
JCR rank
63/138 (2011)
JCR quartile
2 (2011)
ISSN
0271-9142
DOI
10.1007/s10875-010-9490-6
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1232846
handle
http://hdl.handle.net/1854/LU-1232846
date created
2011-05-24 11:31:38
date last changed
2016-12-19 15:42:50
@article{1232846,
  abstract     = {Objective Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses. 
Methods Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75-30 mu g hemagglutinin and formulated with or without adjuvant were administered to groups of 50 volunteers aged 18-60 years. 
Results Adjuvantation of the vaccine led to better persistence of neutralizing and hemagglutination-inhibiting antibodies and higher frequencies of antigen-specific memory B cells. Cross-reactive and polyfunctional H5N1-specific CD4 T cells were detected at baseline and were amplified by vaccination. Expansion of CD4 T cells was enhanced by adjuvantation. 
Conclusion Formulation of the H5N1 vaccine with AS03(A) enhances antibody persistence and induces stronger T- and B-cell responses. The cross-clade T-cell immunity indicates that the adjuvanted vaccine primes individuals to respond to either infection and/or subsequent vaccination with strains drifted from the primary vaccine strain.},
  author       = { Moris, Philippe and van der Most, Robbert and Leroux-Roels, Isabel and Clement, Fr{\'e}d{\'e}ric and Dram{\'e}, Mamadou and Hanon, Emmanuel and Leroux-Roels, Geert and Van Mechelen, Marcelle},
  issn         = {0271-9142},
  journal      = {JOURNAL OF CLINICAL IMMUNOLOGY},
  keyword      = {AS03(A),CHALLENGE,H5N1,vaccine,MEMORY B-CELLS,CANDIDATE VACCINE,REVERSE GENETICS,A H5N1,GENERATION,IMMUNITY,ADULTS,CD4 T cells,pandemic influenza,INFECTION,ADJUVANTS},
  language     = {eng},
  number       = {3},
  pages        = {443--454},
  title        = {H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses},
  url          = {http://dx.doi.org/10.1007/s10875-010-9490-6},
  volume       = {31},
  year         = {2011},
}

Chicago
Moris, Philippe, Robbert van der Most, Isabel Leroux-Roels, Frédéric Clement, Mamadou Dramé, Emmanuel Hanon, Geert Leroux-Roels, and Marcelle Van Mechelen. 2011. “H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-reactive and Polyfunctional CD4 T-cell Responses.” Journal of Clinical Immunology 31 (3): 443–454.
APA
Moris, P., van der Most, R., Leroux-Roels, I., Clement, F., Dramé, M., Hanon, E., Leroux-Roels, G., et al. (2011). H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. JOURNAL OF CLINICAL IMMUNOLOGY, 31(3), 443–454.
Vancouver
1.
Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. JOURNAL OF CLINICAL IMMUNOLOGY. 2011;31(3):443–54.
MLA
Moris, Philippe, Robbert van der Most, Isabel Leroux-Roels, et al. “H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-reactive and Polyfunctional CD4 T-cell Responses.” JOURNAL OF CLINICAL IMMUNOLOGY 31.3 (2011): 443–454. Print.